A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase IIa/IIb Study to Evaluate the Safety, Tolerability, and Efficacy of NP-101 in Treating High-Risk Participants Who Have Tested Positive for Novel Coronavirus 2019
Latest Information Update: 30 May 2025
At a glance
- Drugs Sumatriptan (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms BOSS-002
- Sponsors Novatek Pharmaceuticals
Most Recent Events
- 22 May 2025 Status changed from recruiting to discontinued, because interim analysis results met protocol and SAP predetermined criteria for early stoppage due to futility
- 22 Mar 2024 Planned End Date changed from 22 Dec 2023 to 22 Dec 2024.
- 22 Mar 2024 Planned primary completion date changed from 22 Oct 2023 to 22 Oct 2024.